Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

House Panel Limits Pay-For-Delay Deals

by Glenn Hess
June 15, 2009 | A version of this story appeared in Volume 87, Issue 24

A panel of the House Energy & Commerce Committee has approved legislation to prevent "pay for delay" settlements of patent infringement lawsuits in which manufacturers of brand-name drugs pay potential generic drug competitors to stay out of the market. The Protecting Consumer Access to Generic Drugs Act (H.R. 1706) would ban nearly all settlements in which the brand company gives something of value to the generics manufacturer. Rep. Bobby L. Rush (D-Ill.), chair of the Commerce, Trade & Consumer Protection Subcommittee, says the bill "will save consumers billions of dollars from increased generic competition." But Republicans argue that limiting settlement options could force many more cases into lengthy litigation. The Federal Trade Commission (FTC), one of two U.S. agencies charged with enforcing the nation's antitrust laws, supports the proposal. "Stopping pharmaceutical companies from colluding with each other to delay entry of generic drugs, which sometimes cost 80 to 90% less than their brand-name versions, is a simple and surefire way to control costs," FTC Chairman Jon Leibowitz says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.